Intellectual Property India Publishes Patent Application for 'Imidazo[1,2-A]pyridine Compounds For Use In Treating Cancer And Inflammatory Diseases And Methods To Prepare Said Compounds' Filed by Theranib Inc.

MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202517121322 A) filed by Theranib Inc., Halifax, Canada, on Dec. 3, 2025, for 'imidazo[1,2-a]pyridine compounds for use in treating cancer and inflammatory diseases and methods to prepare said compounds.'

Inventor(s) include La Motta, Concettina; Marcato, Paola; Fernando, Wasundara; Maclean, Maya; Dean, Cheryl; Petrarolo, Giovanni; Bernardoni, Bianca Laura; and D'Agostino, Ilaria.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to ALDH1 A inhibitor compound isoforms according to Formula (I) and pharmaceutical compositions comprising said compounds. Medical compounds for the inhibition of the activity of subtype 1 A aldehyde dehydrogenase proteins are provided, including 2,6,8-trisubstituted imidazo[1,2-a]pyridines. Pathologies and diseases resulting from an upregulation of one or more ALDH1A isoforms may be prevented or treated thereby."

The patent application was internationally filed on June 26, 2024, under International application No.PCT/CA2024/050854.

Disclaimer: Curated by HT Syndication.